Capricor Therapeutics (CAPR) Misses Q1 EPS by 2c, Slight Miss on Revenues

Capricor Therapeutics (NASDAQ: CAPR) reported Q1 EPS of ($0.17), $0.02 worse than the analyst estimate of ($0.15). Revenue for the quarter came in at $880.81 thousand versus the consensus estimate of $900 thousand.

For earnings history and earnings-related data on Capricor Therapeutics (CAPR) click here.

You May Also Be Interested In

• Lucid reports Q2 output, names new CFO and five other leaders
• General Mills (GIS) Tops Q4 EPS by 14c, Beats on Revenue; Offers FY27 EPS Guidance
• Six Flags names Mark Pauls as chief operating officer